Health and life sciences
Medical AI approvals, clinical evidence, AI-discovered drugs and the rules on care decisions.
Latest
-
UK accepts all 44 recommendations of doctor-led commission on regulating health AI New
Medical-AI makers selling in the UK should expect ongoing monitoring duties after approval, not a one-off clearance, bringing the UK closer to the FDA's lifecycle approach.
-
Google DeepMind publishes SynthID Bio watermarking for AI-designed proteins in Nature New
It offers DNA-synthesis screeners a way to verify that unfamiliar sequences came from vetted models, a practical biosecurity layer for open protein design.
-
Anthropic says Claude agents found a new CRISPR-like enzyme system in phage DNA
It shows a frontier lab running end-to-end discovery with its own wet lab, raising both the promise and the biosecurity questions of agentic biology.
-
Insilico doses first patients in Phase III trial of AI-discovered drug rentosertib
It is the first hard test of whether AI-discovered drugs can show efficacy at the scale regulators require for approval.
-
California enacts SB 1119 requiring child-safety risk assessments for companion chatbots
Chatbot makers serving Californian minors move from disclosure duties to pre-release risk assessment and audit obligations backed by private lawsuits.
-
DeepMind releases AlphaGenome Atlas scoring all 9bn single-letter human DNA changes
Free, precomputed variant-effect predictions lower the barrier for clinical genetics and rare-disease research worldwide.
-
FDA proposes a risk framework for generative AI medical devices
It is the first concrete sign of how FDA might clear LLM-based clinical tools, and comments will shape whether chatbots and scribes need premarket review.
-
Colorado repeals its AI Act before it starts, replaces it with lighter ADMT law
The first US comprehensive AI-discrimination law was gutted before taking effect, moving US hiring-AI regulation toward notice-and-explanation rather than audits.
-
Isomorphic Labs raises $2.1bn for its AI drug-design engine
It is among the largest bets yet that AI can shorten drug discovery, though the company still has no drug in human trials.
-
EU deal keeps AI medical devices under AI Act high-risk rules, delayed to 2028
Medtech makers selling AI devices in Europe must plan for dual MDR and AI Act conformity, with one extra year to prepare.
-
Science study: OpenAI's o1 beat physicians at diagnosis on real ER cases
Strong retrospective results increase pressure to deploy diagnostic LLMs, which makes prospective trials and clear regulatory pathways more urgent.
-
China issues companion-AI rules banning virtual partners for minors
It is the most prescriptive national regime for AI companions so far, directly constraining product design for character-chat apps in China.
Rules that apply
23 instruments
-
In force
-
In forceEffective 15 Jul 2026
-
Proposed
-
In forceEffective 23 Jul 2025
-
In forceEffective 11 Dec 2025
-
In forceEffective 3 Apr 2025
-
In forceEffective 4 Dec 2024
-
Partly in forceEffective 1 Jan 2026
-
In forceEffective 1 Jan 2026
-
Enacted, not yet in forceApplies 1 Jul 2027